Grafoid Inc. has formed Calevia Inc., a joint venture partnership with ProScan RX Pharma Inc. to develop a graphene-based nanotechnology platform for the precise targeting and thermal eradication of solid cancer tumors.

Grafoid Inc. has formed Calevia Inc., a joint venture partnership with ProScan RX Pharma Inc., to develop a graphene-based nanotechnology platform for the precise targeting and thermal eradication of solid cancer tumors.

“Calevia sets a clear example to the world how graphene technologies serve humanity,” said Mr. Economo. “As a business, the MesoGraf™-based therapy we aim to bring to market leaves us well positioned with the potential to re-define the treatment for tumorous cancers.”
Mr. Economo said the Calevia partnership combines ProScan’s established cellular antibody targeting technologies with Grafoid’s MesoGraf™Xide graphene to eradicate cancerous cells in a non-invasive manner.
Calevia will first target prostate cancer using ProScan’s anti-PSMA antibody. The platform will be developed subsequently for several solid tumor types.
Grafoid’s MesoGraf™ derivative, MesoGraf™Xide is the latest development in thermal energy generating nanomaterial science that instantly transforms near infrared (NIR) light into heat.
“Grafoid’s move into the bio-medical nanotechnology sector is representative of MesoGraf’s versatility and its value in terms of its adaptability for use in virtually any industrial sector,” said Mr. Economo. “MesoGraf™,” he added, “sets the universal standard for graphene.”

Click here to read the Grafoid Inc. press release